Author + information
- Zhao Liangping,
- Shu Haizhou,
- Wang Li,
- Yao Biao,
- Xu Weiting and
- Chen Jianchang
Adropin is a newly identified secreted protein implicated in the regulation of insulin sensitivity and vascular endothelial function. Recent studies showed that lower serum adropin level was related to acute myocardial infarction and coronary atherosclerosis. The primary objective of this study was to ascertain the effect of adropin on myocardial perfusion and hospitalization prognosis in patients with acute ST segment elevation myocardial infarction (STEMI) after primary percutaneous coronary intervention (PCI).
We prospectively recruited a cohort of patients with acute STEMI. Their serum adropin levels before PCI were measured. The myocardial perfusion was quantified with thrombolysis in myocardial infarction (TIMI) grade, corrected TIMI frame count (CTFC) and one hour ST-segment resolution after PCI. The major adverse cardiac events (MACE) in hospital were recorded including cardiac death, recurrent non fatal myocardial infarction, target vessel revascularization, new onset atrial fibrillation and stroke.
A total of 108 patients (male 89, femal 19) with STEMI were recruited. All of study patients were given conventional anti thrombotic drugs and carried out primary PCI. The mean serum adropin level of total patients was 160.5±32.2 pg/mL. The mean one hour ST-segment resolution and CTFC after PCI were 54.4%±29.3% and 22.0±8.4. The frequency of pre-PCI TIMI grade includes 72 (66.7%) patients with grade 0, 14 (13.0%) with grade 1, 9 (8.3%) with grade 2, 13 (12.0%) with grade 3. The post-PCI TIMI grade includes 3 (2.8%) patients with grade 1, 22 (20.4%) with grade 2, 83 (76.8%) with grade 3. No significant difference of the serum adropin level between the post-PCI TIMI grade 0-2 group and TIMI grade 3 group (155.6±32.2 VS 162.0±32.3 pg/mL, P=0.389). The pearson correlation analysis revealed that serum adropin level were not significantly correlated with one hour ST-segment resolution and CTFC after PCI.
The mean hospital duration of the study patients was 8.1±3.6 days. MACE occurred in 8 pateints including 2 cardiac death and 6 new onset atrial fibrillation. There were no significant difference of serum adropin level between MACE group and non-MACE group (159.3±32.1 VS 175.3±32.2 pg/mL, P=0.178). The multiple logistic regression revealed that serum adropin level was not a significant predictor of hospitalization MACE occurrence.
Although low serum adropin level has a tendency to be associated with worse myocardial perfusion and hospitalization MACE occurrence, the statistical analysis results present no significant difference. Therefore, a study with larger sample size is needed.